Showing 181 - 200 results of 146,356 for search '(( 10 a decrease ) OR ( 5 ((a decrease) OR (((nn decrease) OR (mean decrease)))) ))', query time: 1.10s Refine Results
  1. 181
  2. 182
  3. 183
  4. 184
  5. 185
  6. 186
  7. 187

    A summary of the included study characteristics. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  8. 188
  9. 189

    Seven out of the 11 human cytidine deaminases are more highly expressed in tumor versus normal tissue and their higher expression is correlated with a decrease in survival. by Mason A. McCool (11889842)

    Published 2024
    “…<p>(A) Higher expression of 8 out of the 11 human cytidine deaminases correlates with decreased survival probability. …”
  10. 190
  11. 191
  12. 192
  13. 193

    Decreased activity of FASII favors the cold growth of the <i>ΔcshA</i> strain. by Vanessa Khemici (814639)

    Published 2020
    “…<i>fapR</i> mRNA levels were quantified by RT-qPCR using 16S rRNA as reference gene on total RNAs extracted from <i>wt</i> strain (PR01), <i>ΔcshA</i> strain (PR01-ΔcshA), and suppressor strains <i>ΔcshA/accC</i><sup><i>M385V</i></sup> (C51), <i>ΔcshA/accC</i><sup><i>T183I</i></sup> (sup30), <i>ΔcshA/accD</i><sup><i>F253V</i></sup> (sup17), <i>ΔcshA/accD</i><sup><i>A164V</i></sup> (sup16), <i>ΔcshA/birA</i><sup><i>D320F-FsX28</i></sup> (C58), <i>ΔcshA/birA</i><sup><i>R280stop</i></sup> (sup1) and <i>ΔcshA/bioY</i><sup><i>P123R-FsX1</i></sup> (C66), all at exponential growth phase in MH medium at 25°C. n = 5 for <i>ΔcshA</i>, <i>4 for wt</i> and 3 for all others. …”
  14. 194

    Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis by Eric N. Ouattara (6890174)

    Published 2019
    “…In cost-effectiveness analysis, <i>Immediate ART</i> had a 10-year ICER of $680/YLS compared to <i>ART<350/μL</i>, ranging from cost-saving to an ICER of $1,440/YLS as transmission rates varied. …”
  15. 195
  16. 196
  17. 197
  18. 198
  19. 199
  20. 200